InGeneron, Inc.

InGeneron, Inc. is a regenerative medicine company specializing in cell therapies that utilize patients' own regenerative cells for innovative treatment options in orthopedics and other medical fields. Founded in 2006 and headquartered in Houston, US, InGeneron, Inc. focuses on developing regenerative cell therapies.

The company has raised a total of USD 23. 00 mn in its most recent funding round, Series D, which occurred on June 11, 2019. This funding was led by Sanford Health and supports their ongoing growth in regenerative medicine. The company has completed 6 deals to date, indicating a consistent trajectory in its development efforts.

The CEO is Anita Kadala, who has played a significant role in steering the company's vision and strategic direction. InGeneron specializes in the development of regenerative cell therapies, focusing on harnessing the healing potential of patients' own regenerative cells. Their core product, the Transpose® RT cell therapy platform, is designed for investigational use and aims to provide alternative treatment options for conditions such as orthopedic injuries, specifically targeting issues like rotator cuff tears and knee osteoarthritis. The technology operates by extracting a small sample of adipose tissue from the patient, which is processed to isolate regenerative cells that may be injected into affected areas to promote healing.

This innovative approach is underpinned by over 16 years of research and numerous peer-reviewed publications, positioning InGeneron as a pioneer in the field of regenerative medicine. The company's therapies are primarily aimed at healthcare providers and institutions in the United States, engaging in clinical trials and research collaborations to validate their applications across various patient demographics. Revenue generation for InGeneron is structured around its proprietary cell therapy offerings and the clinical trials that support their development. The company engages with healthcare providers and research institutions through a model that includes partnerships for clinical research and development, as well as direct provision of regenerative therapies in controlled settings.

Their flagship product, the Transpose® RT platform, is used within FDA-approved clinical trials, which helps establish efficacy and serves as a potential revenue stream through collaborations with clinical partners. While specific pricing plans are not disclosed, the business model suggests that revenue is derived from charges associated with the processing and therapeutic application of their regenerative cell products during these investigational uses. This engagement with the medical community aligns with InGeneron's commitment to advancing evidence-based therapies. InGeneron plans to expand its product offerings by developing new regenerative therapies and enhancing its existing Transpose® RT platform.

The company aims to penetrate new geographic markets, particularly by increasing its presence in international healthcare institutions by 2023. The recent Series D funding of USD 23. 00 mn will be utilized to support these initiatives and enhance clinical trial capabilities to further validate their product effectiveness and reach broader patient demographics.